Top Markets
Coin of the day
Fresh Tracks Therapeutics, Inc. Fresh Tracks Therapeutics, Inc.

Fresh Tracks Therapeutics, Inc.

FRTX
株式のランク #36397
Fresh Tracks Therapeutics, Inc. is a clinical-stage pharmaceutical firm focused... Fresh Tracks Therapeutics, Inc. is a clinical-stage pharmaceutical firm focused on creating diverse prescription therapies to address a range of severe autoimmune, inflammatory, and other chronic debilitating conditions, primarily within the U.S. market. A key compound in its development pipeline is sofpironium bromide, which has successfully completed Phase III clinical trials for the management of primary axillary hyperhidrosis. The company is also advancing BBI-02, an oral DYRK1A inhibitor targeting autoimmune and inflammatory diseases, and BBI-10, a covalent STING pathway inhibitor with potential for treating autoinflammatory and rare genetic disorders. Furthermore, Fresh Tracks is engaged in developing next-generation kinase inhibitors. The company maintains crucial licensing and collaborative partnerships, including agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. (and Dr. Nicholas S. Bodor), and AnGes, Inc. Founded in 2009 and based in Boulder, Colorado, the organization rebranded in September 2022, previously operating under the name Brickell Biotech, Inc.
株価
$0.94
最終同期: 2025-02-28
時価総額
$2.73M
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 Fresh Tracks Therapeutics, Inc. (FRTX)

カテゴリー

Fresh Tracks Therapeutics, Inc.(FRTX)の収益
Dec 2023 時点の収益 TTM: $8.01M
Fresh Tracks Therapeutics, Inc. の最新の財務報告によると、現在の収益 (TTM) は $8.01M です。2022 年には $6.94M の収益があり、これは 2021 年の $404.00K と比較して 増加 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Fresh Tracks Therapeutics, Inc. の収益履歴(2000 ~ 2026)
各年末の収益
収益 変化
2026 (TTM) $8.01M 0.00%
2023 $8.01M 15.31%
2022 $6.94M 1,618.56%
2021 $404.00K -77.83%
2020 $1.82M -76.99%
2019 $7.92M 388.10%
2018 $1.62M -88.26%
2017 $13.82M -4.90%
2016 $14.53M -30.64%
2015 $20.95M 37.67%
2014 $15.22M 97.16%
2013 $7.72M -55.94%
2012 $17.52M -41.64%
2011 $30.02M 244.60%
2010 $8.71M -31.33%
2009 $12.69M 59.45%
2008 $7.96M 44.34%
2007 $5.51M -62.61%
2006 $14.74M 22.80%
2005 $12.00M -17.48%
2004 $14.55M 80.05%
2003 $8.08M 15.29%
2002 $7.01M -38.35%
2001 $11.37M 49.16%
2000 $7.62M 0.00%
同業他社の収益
企業 収益 収益の差
$12.62B 157,585.49%
US
$6.02B 75,109.68%
NL
- -
CH
- -
KR
$10.11B 126,190.12%
BE